Q-Med U.S. Postmarket Study Needed To Support Deflux Efficacy - Panel Says
This article was originally published in The Gray Sheet
Executive Summary
Q-Med AB should conduct a prospective, randomized, multi-center study in the U.S. of its Deflux injectable gel for vesicoureteral reflux in children as a postmarket condition for FDA approval, FDA's Gastroenterology and Urology Devices Panel recommended.
You may also be interested in...
Q-Med Breaks Into U.S. Urology Market With Deflux Pediatric VUR Indication
Q-Med plans to begin a U.S. pilot study of its Deflux injectable hyaluronic gel product for treatment of stress urinary incontinence early in 2002. The product has been available in Europe for the indication since 1999.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.